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ABSTRACT
Multipotent mesenchymal stem cells (MSCs) are special kind of stem cells which originate from mesenchyme. These cells can be used as an imperative 
tool to study reproductive toxicity, carcinogenicity, mutagenicity, genotoxicity, and pharmacokinetics. This novel system may reveal toxicant-
induced etiology, decipher detailed understanding on molecular mechanisms of toxicants induced pathways and also enumerate the safe dose of 
an investigational product. Hence, this could ultimately replace, improve or overtake current predictive models in toxicology. The particular review 
describes the utilization of MSCs in different field of toxicological and pharmacological research.
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INTRODUCTION
Toxicity may result due to administration or exposure to drugs 
or chemicals or xenobiotic compounds or radiation or particulate 
matter or endogenous production of toxins by any microbial flora 
or transplanted cells. Such primary and auxiliary toxic agents 
may disrupt intracellular cell signaling and interrupt cell-to-
cell interactions from intra- and extra-cellular communiqué and 
affect cellular architectures in biochemical, anatomical, cellular, 
psychological, and pathological level. This may be due to the complex 
interaction established between toxic agents and genes, proteins, 
RNA and cellular organelles [1,2]. These phenomena may alter 
biological cascades of circadian rhythm in human, affect the dynamic 
cellular function and metabolism, generate malignant tissues, change 
rhythmic beating passion of heart and can provoke psychological 
complications [3]. In the pharmaceutical settings, toxicological 
studies of new compounds or agents play the most key role to provide 
safety and accurate assessment of risk factors associated with novel 
drugs before administration to human beings. The US Food and Drug 
Administration states that it is essential to screen new molecules for 
pharmacological activity and toxicity potential in animals (21CFR 
Part 314) [4]. Traditionally, various animal models such as mice, 
rats, guinea pigs, and dogs are used to predict or anticipate toxicity 
of newly synthesized drugs or stringent chemicals or any suspected 
agents, as these agents might induce cardiotoxicity, hepatotoxicity, 
genotoxicity or epigenetic and reproductive toxicity in humans. 
However, there are several demerits of using animals in toxicological 
studies. The tests conducted in animal models are not yet well 
standardized. Apart from this, the animal models are not good 
representative of humans because inter-specific differences exist in 
accordance to pharmacokinetics and toxicokinetics background [5]. 
It often gives doubtful results during early (preclinical) or necessary 
late (clinical) assessment of newly synthesized drugs leading to 
termination of drug development programs (Fig. 1).
The ethical issues and cost of analysis add further constrain in the use 
of animals in toxicological studies. To reduce the risk and ambiguity 
that is often associated with testing, developing and screening of 
toxicity using experimental animals currently, suitable alternative 
in vitro models such as whole embryo cultures, primary cultures and 
permanent cell lines, cell lines established from specialized somatic 
cells are being used [7]. These biological systems may produce 
relevant and accurate information about toxic agents affecting the vital 
cellular functions. This may be due to the fact that common cellular 
sources are used to test the subject (suspected agents) and to see the 
effects [8]. Recently, the novel approach of using stem cell derived 
systems of embryonic origin such as embryonic carcinoma, embryonic 
stem (ES) and embryonic germ cells (GCs) and non-embryonic origin 
induce pluripotent cells (iPSc) and multipotent adult stem (AS) cells 
open new avenues in the field of pharmacokinetics and toxicological 
research [6]. These in vitro systems are now being used to extrapolate 
the correlation between toxic effects of toxicants and the doses causing 
organ toxicity, embryotoxicity and developmental toxicity (Fig. 2) so 
that a safe predetermined dose of chemicals can be prescribed before 
in vivo studies and clinical translation. This review describes the 
nontherapeutic potential applications of multipotent mesenchymal 
stem cells (MSCs), in particular, case pertaining to toxicological studies 
and pharmacological screening.
LETHALITY-INDUCED BY TOXIC AGENTS
The toxic agents target constituent of tissues by altering enzyme activity, 
interfering the binding of hormone to a specific receptor by creating 
structural homolog to alter its function, modulating the number of 
hormone receptors, changing the way of hormone synthesis and 
their affinities for specific molecules. Intercalation with nucleic acids, 
disturbances in electrolyte balance and the disorganization of cellular 
water and membrane lipids are illustrated as toxic processes involving 
ionic or van der Waals forces. The interaction results perturbation 
of biological pathways. When perturbations are sufficiently large 
or when the host is unable to adapt to the changed physiological 
conditions, it may contribute to nutritional, genetic, disease, or life-
stage status factors. The biological function is compromised, and this 
leads to toxicity and disease. The circuitry affected by the chemical 
is expected to determine the shapes of curves of dose-response 
relationships for these perturbations. The responses are viewed as the 
results of an intersection of exposure and biological function. Hence, 
the determination of lethal doses that result progressive activation 
of toxicity pathways from perturbation of initial targets, through 
activation of stress controlling pathways, to overtly toxic responses 
(apical endpoints) is essential [9]. Traditionally, to determine toxicity, 
the LD50 assay has been used, which is a measure of the dose required 
to cause death in 50% of the animals under the study. An alternative 
to this assay was first suggested by the British Toxicology Society in 
1984 and was based on administering a series of fixed doses and relying 
on the observation of clear signs of toxicity (altered morphology, 
biochemistry, and undesired by-products) rather than the endpoint 
of the assay being death. Recently, developed in vitro signatures and 
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computational models are being used to determine agents that induce 
toxicity, detect perturbation in cellular pathways that are expected to 
contribute to or result in adverse health effects. Pathway testing would 
require a suite of tests which could identify the range of significant 
perturbations of human biology. This might occur as a result of chemical 
exposure (Fig. 3).
STEM CELLS AND THEIR RESPONSE TO TOXICITY
The development of multicellular organism from egg to an adult is 
a complex series of interlocked events, which depends on precise 
coordination of time and space. From the time of implantation 
of totipotent zygote, the complex interaction between external 
environment and physiological stress results in a dynamic changeover 
from totipotent stem cells to pluripotent stem cells and multipotent 
stem cells that commit to form specific organ types. These mutually 
exclusive events are directed via differentiation, determination, and 
specification which ultimately result in the formation of an adult 
individual. Stem cells are uncommitted cells [10]. These cells are an 
important tool to study molecular mechanisms of different biological 
pathways, differentiation, and mechanisms of cellular commitment [11]. 
These are ideal experimental systems for the study of molecular events 
of development and analysis of agents that may alter these directed 
mechanisms. Stem cells can facultatively use both symmetric and 
asymmetric divisions to express constitutively the properties of self-
renewal and differentiation (Fig. 4).
Symmetric divisions can expand stem-cell number by generating 
daughter cells that are destined to acquire the same fate thus, playing 
an important role in adult mammalian homeostasis. Asymmetric 
divisions result cells that are destined to acquire a different fate. It is 
noteworthy that asymmetric divisions can be governed by both intrinsic 
partitioning of fate regulators and asymmetric exposure to extrinsic 
cues [12]. ES cells derived from early embryonic cells represent an 
excellent in vitro model system to study the molecular mechanism 
associated with pluripotency, self-renewal and development. The 
remarkable capacity of ES cells to transform into variety of somatic and 
germinal cells reflects the dynamic events that occur in vivo [13]. ES 
cell lines were first derived from mice [14,15] but currently available 
from a variety of mammalian systems, including human [16]. They 
can propagate at undifferentiated state up to indefinite period under 
defined culture conditions [13,14,17]. The most reliable method for 
generating differentiated cells from ES cells is by induction of embryoid 
bodies (EBs). Many features of EBs resemble that of developing embryo. 
These EBs on attachment to permissive surface like gelatin, collagen, 
and treatment with appropriate inducer continue a programed 
differentiation into ectodermal, mesodermal, and endodermal lineages 
[18]. Hence, pluripotent ES cell lines recapitulate cellular developmental 
processes and gene expression patterns of early embryogenesis during 
in vitro differentiation which is hard to visualize in in vivo condition. 
Thus, ES cells hold great promise as an unlimited cell source for various 
clinical and biotechnological applications [19-21]. This disease-in-a-
dish model is useful to understand molecular mechanisms of diseases 
and cellular responses to various therapeutic and toxic agents. Hence, 
in vitro culture of human ES (hES) cells is a suitable system to study 
etiology and prognosis of many degenerative diseases and a valuable 
tool for drug or toxicity screening and mechanistic studies including 
analysis of disease pathway and developmental toxicity [22]. 
Developmental toxicity is often associated with birth defects, low 
birth weight, and biological dysfunction. About 10% of birth defects 
are related with environmental factors including therapeutic agents 
and developmental toxicants [23]. Embryotoxicity can be assessed 
by ES cell test using differentiated cells of mouse ES cells. The test 
is successfully validated by the European Center for the validation of 
alternative methods (ECVAM) and considered as fundamental models 
to screen the unknown chemicals capable of causing embryotoxicity, 
such as cytotoxicity and differentiation and to know the altered 
physiological mechanisms caused due to toxicity from molecular 
level. In addition, differences in sensitivity between differentiated 
(adult) and embryonic cells are also taken into consideration. To 
predict the embryotoxic potential of a test substance, three endpoints 
are assessed such as the inhibition of differentiation into beating 
cardiomyocytes, the cytotoxic effects on stem cells, and the cytotoxic 
effects on 3T3 fibroblasts. A special feature of the EST is that it is 
Fig. 1: Important causes of drugs failure (Data obtained from 
Suter-Dick et al. [6])
Fig. 2: Potential application of embryonic and adult stem cells to design toxicologically relevant organotypic microtissue models
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solely based on permanent cell lines so that primary embryonic 
cells and tissues from pregnant animals are not needed. This EST 
protocol is an ECVAM-validated method, in which the morphological 
assessment of contracting cardiomyocytes is used as endpoint for 
differentiation, and the molecular-based fluorescent-activated cell 
sorting-EST method, in which highly predictive protein markers 
specific for developing heart tissue are selected. With these methods, 
the embryotoxic potency of a compound can be assessed in vitro 
within 10 or 7 days, respectively [24]. Available literature suggests 
that this in vitro cultured ES cells model is currently considered as 
the best model to predict embryotoxicity, developmental toxicity, 
mutagenicity, and teratogenicity (Fig. 5).
Fig. 3: Relationship between dose and toxicity
Fig. 4: Division and differentiation shown by stem cells
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Recent studies demonstrate that endocrine disruptors (EDs) 
may be any estrogen-like and antiandrogenic chemicals, 
environmental agents [e.g., polychlorinated biphenyls (PCBs), 
dichlorodiphenyltrichloroethane (DDT), dioxin, and some pesticides) 
can affect function of reproductive cells (GCs) and organs or tissues 
associated with reproduction. The compounds such as bisphenol-A, 
di-2-ethylhexyl phthalate (DEHP) and dibutyl phthalate, vinclozolin 
promote epigenetic transgenerational inheritance into subsequent 
generations [25]. Hence, extensive screening and multi-generation 
studies are required prior to registration of agrochemicals and before 
commercialization of pharmaceutical products. Currently, ES cells are 
not only used to test chemical compounds but also to identify the toxic 
effects of physical factors, such as electromagnetic fields emitted by 
digital mobile communication systems [26]. Despite several advantages, 
application of ES cells in biomedical research is often restricted due to 
ethical and social issues. To circumvent this problem, human-iPSCs 
are generated by reprograming the somatic cells and AS cells derived 
from several adult origin are currently being used. iPSCs are converted 
pluripotent stem cells. In this process, the adult somatic cells are 
“forced” to express five pivotal genes, namely Oct-3/4, SOX2, c-Myc, Klf4, 
and Nanog essential to maintain pluripotency [27] that are silenced in 
course of development. Currently, they play a key role in therapeutic and 
other biotechnological applications such as drug discovery, toxicology, 
disease modeling, and gene therapy [28]. It is demonstrated that iPSCs 
are currently being used for high-throughput screening and chronic 
toxicity assessment of cardiac, hepatic, and nervous tissues [29]. Recent 
report by Deshmukh et al. [30] describes that ES cells and iPSCs are 
efficiently used to screen cardiac and neurotoxic agents. iPSCs derived 
from different somatic cells may be used to produce unrepaired somatic 
cells for disease modeling or drug screening (Fig. 6).
However, sometimes iPSCs fail to reproduce the same effect successfully. 
This may be due to the fact that it is difficult to create pluripotent 
environment within a multipotent counterpart. During their lifetime, 
the adult humans are constantly being exposed to deleterious 
environmental impacts of a multiplicity of anthropogenic substances, 
number of drugs, chemicals, and pollutants which may induce toxic 
effects. So is it wise to use embryogenic cell-based models (ES cells 
and iPSCs cells) to predict the toxicity that is encountered by adult 
individuals? It is reported that neural stem cells or progenitor cells 
may be relevant models for alternative developmental neurotoxicity 
(DNT) testing [31]. When xenobiotic agents interfere with progressive 
development and growth, they alter cellular growth and differentiation, 
leading to permanent or temporary changes in tissue or organ structure 
and function, i.e., disease, disorder, and developmental malformations. 
All these mutually exclusive events are controlled by expression of a 
unique set of genes, i.e., influenced by many environmental (physical, 
chemical and biological) factors [32].
When stresses are intricated by any stressors (toxicants), this disrupts 
cell-to-cell communiqué and provokes an adaptive response and ends 
in non-adaptive consequences. All these phenomena influence stem 
cells niche and deregulate cell cycle progression, cellular function, 
intracellular communiqué, and signaling pathways. These pathways 
can activate or inactivate specific gene that regulates transcription of 
extant proteins or transcription factors (FTs) involved in proliferation, 
differentiation, apoptosis, stress responses, and senescence. But 
how do the toxic agents intricate teratogenesis, carcinogenesis and 
mutagenesis in targeted tissues? This may be due to the fact that 
toxicants involve initiation or inhibit intracellular signaling cascades 
that trigger acetylation, deacetylation, and methylation of histones 
leading to DNA damage by epigenetic modification of chromatin [33]. 
All these events may happen due to the fact that these toxicants 
disturb gap junction intercellular communication (GJIC) that maintains 
tissue homeostasis and controls cellular function, such as growth, 
differentiation, development, and apoptosis. Gap junctions are plaque-
like protein structures that form contiguous channels between 
cells allowing for the passive diffusion of low molecular weight 
metabolites and second messengers between the molecular weight of 
1-1200 Dalton (Da). Each channel is made up of two connexons, each 
residing in separate contiguous cells. The connexon is made up of six 
subunits that are termed as connexins [34]. Due to the central role of 
intercellular signaling through gap junctions, GJIC plays a significant 
role in coordinating signaling events that control gene expression. 
This property makes it an ideal biological endpoint to monitor the 
toxic effects of environmental agents, toxins and potential health 
hazards of pharmaceuticals. Gap junction communication through 
connexin-mediated junctions’ connexin 43 (Cx43) plays a major 
role in development and differentiation of bone development. The 
extracellular communication or “stromal-epithelial-type” interactions 
trigger intracellular communication signals to modulate GJIC between 
either homologous or heterologous cells within tissues [32]. GJIC can be 
modulated either reversibly or irreversibly, by most, if not all, “tumor-
promoting chemicals.” Inhibition of GJIC has been postulated to mediate 
via non-genotoxic carcinogenic mechanism. This mechanism may relate 
to tumor promotion and progression. Recent studies demonstrate that 
inhibition of GJIC in rats and mice is well correlated with induction of 
both liver tumors and markers for peroxisomal proliferation which 
result from excess deposition of phthalate esters in the liver. However, 
species-specific differences exist in response to analog of phthalate 
esters as shown by studies with DEHP and diisononyl phthalates (DINP). 
However, GJIC was unaffected in some mammalian species hamsters 
Fig. 5: ES cell derived differentiation-related endpoints using developmental toxicants
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and primates including humans in which phthalate treatment does not 
induce peroxisomal proliferation. In vitro studies which extended the 
database to include human liver cells mirrored the in vivo situation. 
Peroxisomal proliferation has been characterized as a species-specific 
process essential for phthalate-induced rodent liver tumor induction. 
Thus, the GJIC data along with those from studies of peroxisomal 
proliferation support the view that the carcinogenic effects of DEHP 
and DINP in rodents are not relevant to humans [35]. These evaluated 
data on cells from other species cannot also explain the in vivo situation 
of human in the presence of any toxic agent. So currently, it is a prime 
concern for the researchers associated with pharmacokinetics and 
toxicological studies to design a reliable test system which sufficiently 
mirrors the in vivo situation of human.
But how to determine the toxic effects of any toxicant on cells, 
tissues or organs? The ability of chemicals with tumor-promoting or 
tumor-inhibiting activity to modulate gap junctional intercellular 
communication have been detected with two most extensively used 
assays, namely (1) metabolic cooperation assays and (2) dye-transfer 
assays [36]. In metabolic cooperation assays, a population of donor cells 
is incubated in the presence of an excess of a radiolabeled precursor 
(typically uridine) and then cocultured with unlabeled recipient 
cells. Under such conditions, quantitative autoradiography enables 
evaluation of the transfer of the resulting metabolites from loaded to 
unloaded cells as a function of time. In this type of experiment, coupling 
is demonstrated by the autoradiographic labeling of the cytoplasm 
of recipient cells due to the incorporation in their ribonucleic acid of 
radiolabeled nucleotide synthesized within donor cells and transferred 
across Cx channels. Radioactive nucleotide transfer allows for a direct 
evaluation of the permeability of Cx channels to endogenous molecules. 
The scrape loading/dye transfer technique is a simple functional 
assay for the simultaneous assessment of GJIC in a large population 
of cells [37]. Dye-transfer assays measure exchange of fluorescent dye 
from loaded cells to adjacent cells. It is demonstrated that a number of 
factors play an important role for routine screening of toxic agents. These 
include the requirement of biotransformation for some agents to exert 
effects on gap junctions. The tumor promoters and tumor inhibitors 
affect gap junctional permeability that influences many physiological 
mechanisms like protein kinase activation, changes in proton and Ca2+ 
intracellular concentration and oxyradical production [36]. Growth 
factors, hormones, extracellular matrix, and cytokines can also block 
GJIC [38]. In many AS cells, neither the connexin genes are expressed 
nor are the gap junctions functional [39]. The cancer cells completely 
lose expression of connexin gene. Hence, measurement of GJIC plays a 
significant role in determination of toxic level [40]. This involves the 
transfer of a low molecular weight fluorescent dye (<1000Da) between 
contiguous cells [41]. It is thought that chronic disruption of GJIC may 
release some factors that favor clonal expansion and ultimately tumor 
formation [42]. Reduced expression of GJs following treatment with 
nongenotoxic carcinogens appears to affect specific target organ [43,44]. 
Due to exposure to mutagens or carcinogens, xenobiotic compounds 
and EDs the immune response hikes to initiate intracellular signaling 
cascades and releases various bioactive secreting factors (Fig. 7).
Available literature suggests that [6,32,45] the different types of stem 
cells are involved in toxicity testing and screening of organ-specific 
toxicity (Fig. 8).
MSCS AND TOXICOLOGICAL STUDIES
The mesenchyme is an embryonic connective tissue which is derived 
from the mesoderm (the middle embryonic layer) that harbors 
mesenchymatous cells which have a high rate of division and the 
ability to spread and migrate in early embryonic development between 
the ectodermal and endodermal layers. The MSCs are heterogeneous 
multipotent stem cells which play a pivotal role in the development 
of all evolving structures and organs from the mesenchyme during 
ontogeny [46]. MSCs lie at the top of the mesenchymal cell hierarchy 
and progress through discrete stages of differentiation in an orderly 
manner to give rise to functionally and phenotypically mature tissues, 
including bones, smooth muscles, tendons, and cartilages [47]. In 
general, these MSCs are considered to originate in the mesenchyme, but 
embryonic MSCs have recently been shown to be derived also from the 
neuroepithelium and neural crest. However, it remains unclear whether 
ontogenically distinct MSCs are endowed with specific functions. MSCs 
are multipotent stem cells residing in almost all postnatal organs and 
tissues. Like other stem cells, they have unique properties such as 
self-renewal, unlimited proliferation ability, and plasticity to generate 
various cell types. Earlier it was assumed that MSCs can differentiate 
only to mesodermal lineages (osteocytes, chondrocytes, and adipocytes) 
Fig. 6: Application of human-induced pluripotent stem cells in basic and applied research
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Fig. 7: Different physical, chemical, or biological agents affect normal cellular functions
but now it is well demonstrated that these can fabricate into distinct 
end-stage cell types of 3 primary germ layers such as mesodermal 
(bone, cartilage, muscle, bone marrow stroma, tendon/ligament, fat, 
dermis, and other connective tissues), ectodermal (epithelial, glial, 
and neural), and endodermal (hepatocyte and islet cell) lineages in 
in vitro and in vivo condition. Friedenstein et al. (1970) first reported 
the existence of non-hematopoietic multipotent precursor cells in 
bone marrow (BM) with skeletal and adipose potential [48]. This rare 
population also exists in adipose tissues, skeletal muscles, umbilical 
cord blood (UCB), placenta and Wharton’s jelly tissues, UCB and several 
blood sources such as peripheral blood, menstrual blood of female 
other than BM. These cells can be derived, expanded, and manipulated 
in vitro. MSCs express the molecular markers which include CD90, 
CD105, and CD73 and fail to express the markers such as CD34, CD45, 
and CD14. Contemporary to other available cell lines, MSCs also express 
pluripotent genes that include the TFs Oct4, Sox2 and Nanog, which are 
normally express by hES cells [49]. Hence, this could be considered as 
safe alternative of ES cells and iPSCs. MSCs are special kind of stem cells 
that oscillate between pluripotency and multipotency. That is why MSCs 
are promising cell source for cellular therapy, tissue engineering, and 
regenerative medicine. This may be due to their inherent nature and 
plasticity to differentiate into multiple lineages. These have the ability 
to integrate into the host tissues without showing immune rejection 
by host immune system. This may be due to the fact that MSCs secrete 
a broad spectrum of bioactive macromolecules that are immune-
regulatory and immune-suppressive in nature. This makes them most 
favorable choice for autogenic and allogenic transplantation [47]. These 
cells can be used to renew, repair and reform the vulnerable tissues, and 
therefore, widely applied to therapeutic cloning, tissue engineering, 
and regenerative medicine. The characteristic features of MSCs such 
as fibroblastic morphology, adherent nature, spheroid formation 
ability, easy genetic manipulation, and susceptibility to molecules 
that modify their natural behavior make them efficient candidate for 
non-therapeutic clinical research especially for pharmacological and 
toxicological studies. The spheroids may mimic three-dimensional (3D) 
organotypic models. These 3D in vitro culture models are expected to 
be relevant representative of the in vivo environment. Are the spheroids 
able to replace EBs needed for embryotoxicity and teratogenicity assay? 
Human MSCs can make cardiac connexins (Cx43, Cx 40 and Cx 45) 
and form gap junctional complex. It is recently reported that amniotic 
fluid-derived stem cells differentiate into cardiomyocyte-like cells and 
form gap junctions when directly mixed and cultured with neonatal 
rat ventricular myocytes [50]. Similar to other cells, toxic agents also 
affect viability, morphology, and function of MSCs. The effects of toxic 
agents on MSCs derived from different sources lead to undesirable 
consequences (Fig. 9).
A plethora of experimental works unequivocally established that MSCs 
can directly differentiate into neurons, glial cells, cardiomyocytes, and 
liver-specific cells (hepatocytes, pancreatic ß cells). According to a 
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Fig. 8: Role of stem cells in screening of toxicity
Fig. 9: Induced toxicity by different stressors on in vitro cultured mesenchymal stem cells
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report that human bone marrow stem cells could able to differentiate 
to male GCs [51]. These bone marrow cell-derived GCs also express the 
known molecular markers of primordial GCs, such as fragilis, stella, 
Rnf17, Mvh and Oct4 as well as molecular markers of spermatogonial 
stem cells and spermatogonia including Rbm, c-Kit, Tex18, Stra8, 
Piwil2, Dazl, Hsp90 alpha, beta 1- and alpha 6-integrins. Recent study 
by Latifpour et al. [52] report that human umbilical cord (hUCMSCs) 
can trans-differentiate into primordial like GCs (PGCs) when in vitro 
culture was performed under specific condition (bone morphogenetic 
protein 4 followed by retinoic acid). Hence, MSCs can be efficiently 
utilized to study mechanisms and pathways of different toxicants 
provoking etiology of many diseases, toxicity testing, evaluation of 
cytotoxicity and genotoxicity of pharmaceuticals and toxicity screening 
of chemicals that induce neurotoxicity, cardiotoxicity, hepatotoxicity, 
reprotoxicity, and drug discovery [53]. For example, development of 
anti-obesity drugs requires adipocytes that can be used to test whether 
any chemicals and toxicants can affect this process. Scanu et al. [54] 
report that hMSCs can be used for acute toxicity testing of chemicals.
NEUROTOXICITY
The complexity of the developing human brain complicates efforts 
to assess DNT in vitro, as the underlying mechanisms may include 
selective cell death, delayed or aberrant differentiation, suppressed 
neurotransmission, disruption of the blood-brain barrier, or 
modulation of inflammatory signals by glial or microglial cells. Thus, 
an in vitro model to predict human neurotoxicity needs to recapitulate 
a diversity of cellular interactions during human brain development 
and should be reproducible both within an experiment and between 
experiments performed on different days or at different sites. The 
studies impressively demonstrate that capacity of neuronal precursor 
cells prepared from self-assemble 3D “organoids” and hMSCs offer 
a consistent, scalable source for diverse neural cell types including 
neuron, glial cells, and astrocytes in the presence of appropriate 
inducers. Recent report suggests that hUCMSCs differentiate into 
neural-like progenitor cells and matured oligodendroglial-like 
lineage when cultured in neurobasal medium supplemented with 
B27, 10 ng/ml of human recombinant bFGF, platelet-derived growth 
factor-AA and 100 ng/ml of Sonic Hedgehog [55,56]. Toxic effects 
of chemical compounds, environmental factors, naturally occurring 
substances, anthropogenic agents, and EDs can lead to neurotoxicity. 
Neurotoxicities may express as neuropathologic condition or as altered 
neurocthemical, electrophysiological or behavioral functions which, in 
turn, leads to temporary or permanent harm to the central or peripheral 
nervous system. Environmental toxicants or pharmaceutical agents 
can influence excitotoxic processes which exaggerate their deleterious 
effect. In case of excitotoxicity (a specific form of neurotoxicity), 
excessive stimulation of the neuron occurs due to spinal cord injury, 
stroke, or traumatic brain injury during which neurotransmitters like 
glutamate and similar substances are responsible for damage and death 
of nerve cells that can be measured by several assays (Fig. 10).
The neurotoxicity test model allows studying the adverse effect of 
drug candidates on neuronal cells with the help of neurotoxicity assays 
for screening of compounds. This test system allows the reduction 
in production cost of preclinical development of drugs. Impaired 
calcium signaling and calcium measurements may be important 
criteria to know about neurotoxic agents. There is a decrease in 
depolarization, elicited by calcium elevation that accompanies the 
release of the specific neurotransmitter synthesized by a given neuron. 
Thus, this outcome provides valuable information about the toxicity 
of an uncharacterized compound to assess the toxicity of various 
compounds. Comparing cytotoxic or apoptosis-triggering effects of 
a given compound at different stages of neuronal differentiation also 
provide useful information about the severity of that particular agent. 
The toxicity of corticosteroid used in ophthalmological therapy of 
treatment of age-related macular degeneration (AMD) has been tested 
using MSCs. For this, MSCs were seeded with triamcinolone acetonide 
(9a-fluoro-16a-hydroxyprednisolone, TA), intravitreal triamcinolone, 
and dexamethasone at different concentration (0.01 mg/mL, 
0.1 mg/mL, and 1.0 mg/mL) [57]. The study of evaluation of drug 
toxicity reveals that a strong relationship exists between concentration 
of drugs and time with viability of MSCs. As the concentration of drugs 
and duration increases the viability decreases. This study demonstrates 
the need to use low concentration corticosteroid in pharmaceutical 
formulation of AMD. The developing brain is particularly vulnerable to 
toxic agents, even at exposure levels that have no lasting effects in the 
adult nervous system. Therefore, DNT assessment is a serious concern 
for environmental chemicals, drugs and new chemical entities. By using 
adipose tissue-derived MSCs (AT-MSCs) Qasemian Lemraski et al. [58] 
demonstrated that lead (Pb) is a potent DNT. This study further 
explains how MSCs could be utilized to determine toxic potential of 
chemicals. In vitro cytotoxicity tests are also typically carried out with 
transformed, immortalized cell lines, or primary cells. Immortalized 
cells are readily available and easily maintained, although they usually 
show anomalous behavior and phenotypes, which do not reflect the 
mechanisms observed in their normal homologous cells. Primary cells 
are indeed considered a better option as model systems for predicting 
toxicological behavior, although they are limited in quantity and suffer 
from batch-to-batch variation due to the need to isolate them freshly 
for each study. In particular, hMSCs have never been adopted to develop 
in vitro model systems for acute toxicity tests of chemicals. Therefore, 
the main aim of the study was to verify the possibility of using hMSCs as 
an alternative method to estimate in vivo starting dose for acute toxicity. 
As suggested by ICCVAM, 12 reference chemicals were assessed in the 
present study and a Neutral Red Uptake assay was performed. It is 
reported for the first time that MSCs isolated from human bone marrow 
can undoubtedly be used to test acute neurotoxicity [55].
CARDIOTOXICITY
Cardiovascular disease is the lead cause of death worldwide. Every 
year 17 million people die of cardiovascular disease. Out of this 11 
million die as a result of cardiac disease and 5.5 million deaths are 
related to stroke. It is estimated that myocardial infarction carries a 
mortality rate 7% (with aggressive therapy). Even more distressing 
condition record due to congestive heart failure causing mortality 20% 
in 1 year. The major agents responsible for cardiovascular diseases 
are hypertension, diabetes, stress, the chronic use of few drugs, 
cigarette smoking, elevated cholesterol, obesity, physical inactivity, 
and aging [59]. The spectra of cardiovascular diseases are amenable 
to therapeutic intervention via cell engraftment, organ transplants, 
and angioplasty. However, these treatments are far from the reach of 
common people. These costly treatments may be due to the fact that 
adult cardiomyocytes have a limited regenerative capacity, and their 
loss permanently results in impaired myocardial contractile function 
leading to loss of cardiac function and heart failure. In fact, some class 
of drugs (cardiotoxic agents) are responsible for cardiac damage 
(Table 1).
Efforts are being made to develop different ways of treating 
cardiovascular diseases that involve not only producing 
immunocompatible cardiomyocytes but also establishing more 
sophisticated cellular drug discovery and test systems. Much faster 
heart rate in humans makes the rodent model unsuitable to mimic 
the basic physiological functions of heart of human. The contractile 
nature and function of in vitro differentiated cardiomyocytes have 
additional advantage as these respond in similar manner as fetal 
cardiomyocytes to the drugs. Hence,, these ultimately provide an 
optimum homogenous cell culture system for screening of cardiotoxic 
agents and improved high-throughput drug discovery process. Several 
protocols and strategies have been reported for in vitro differentiation 
of cardiomyocytes from MSCs. Cultured MSCs differentiate into 
beating cardiomyocytes in the presence of 5-azacytidine [60]. It is 
well documented that the compounds that do not interfere with ion 
channel functionality also causes cardiotoxic insults. In many cases of 
cardiotoxicity, a direct interaction of drugs with specific ion channels 
expressed by the cardiomyocytes leads to alteration in ion conduction 
through these specific channels. Effects of the agents like drugs and 
chemicals on potassium currents could lead to QT-prolongation, 
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potentially fatal arrhythmias and sometimes cardiomuscular damage 
without affecting ion channels [61].
Unfortunately, modern training in toxicology and pharmacokinetics 
is directed primarily at specific ligand-receptor interactions at the 
expense of system physiology. Current physiological testing strategies 
may potentially miss cardiac effects that manifest chronically, vascular 
and microvascular effects. It results from toxicity initiated in other 
tissues and microvascular physiology and toxicology in the context 
of model development, application, and underlying pathology. 
Cancer chemotherapies might cause cardiomyocyte apoptosis and 
dysfunction. However, different chemotherapeutics might have 
different toxicity induction mechanisms. This new approach utilizes a 
dual-channel automated image cytometer that allows for simultaneous 
measurement of the cardiomyocyte action potential and calcium 
transient using voltage and calcium-sensitive dyes. ESC- and iPSC-
derived cardiomyocytes have recently been used to study doxorubicin-
triggered toxicity [62]. MSCs-derived cardiomyocytes are suitable to 
study the effects of compounds which do not interfere with the ion 
channel functions but still cause cardiotoxicity. Doxorubicin, which 
belongs to the anthracycline family, has been proven to be effective in 
different tissue-derived cancer diseases, including cancer of the breast, 
lung, stomach, bladder, and skin. Despite the anti-tumoral properties of 
doxorubicin, myelosuppression, and particularly cardiotoxicity restrict 
its clinical use [63]. Doxorubicin also induces toxic effect in endogenous 
MSCs [64]. It is reported that BMMSCs, isolated from rats that receive 
doxorubicin, show slower proliferation rate and lower differentiation 
capacity, decreased connexin-43 production and hindered MSCs 
capacity to respond to cardiomyogenic differentiation stimuli [65]. 
So considering above cases, the conclusion can be drawn that MSCs 
could be a better option to detect cardiotoxic agents. Two clinically 
decisive biomarkers of cardiac damage that are sensitive indicators for 
doxorubicin-induced toxicity have been studied. Troponin T (TnT) is a 
useful biomarker for studying drug-induced toxicity effects on cardiac 
cells. After induction of doxorubicin, MSCs-derived cardiomyocytes 
released detectable levels of cardiac TnT and fatty acid-binding protein 
3 in a dose-dependent manner [62]. Based on the availability of very 
sensitive and rapid analytical tools for these biomarkers, the assay 
lends itself well to miniaturization and high-throughput formats.
HEPATOTOXICITY
Culture of 3D tissue (in vitro) models can capture cell-cell and cell-
matrix interactions that happen in in vivo counterpart [66]. Hepatocytes, 
the major cells of the liver, metabolize most compounds and thereby 
can be used to predict many pharmacological characteristics of a drug. 
It is still to improve and develop new models, in some areas such as 
hepatotoxicity. Presently, only hepatocyte-like cells (HLCs) expressing 
low levels of liver-specific markers, especially drug metabolizing and 
detoxifying enzymes are usually obtained, making them still unsuitable 
as metabolically competent cells for toxicity studies. The only exceptions 
are some hepatoma cell lines, particularly the HepaRG cell line that can 
differentiate from a bipotent progenitor stage to attain the functional 
capacity of normal adult hepatocytes in primary culture without losing 
the indefinite growth property of transformed cells [67]. Recently, 
Kwon et al. [68] report that differentiated HLCs from human AT-MSCs 
may be used as in vitro hepatotoxicity screening system. The toxic 
effect of arsanilic acid (Ars) and acetaminophen (AAP) on the hepatic 
development were determined. The hepatic differentiation from AT-
MSCs was confirmed by an increase in hepatic proteins or genes, the 
cytochrome P450 (CYP) activities, albumin secretion, and glycogen 
storage. The toxic effects of these hepatotoxicants on enzymatic 
activities of lactate dehydrogenase, alanine aminotransferase and 
aspartate aminotransferase do not significantly differ in response to 
Ars treatment. AAP treatment increases the activities of all enzymes 
in a dose-dependent manner, significantly at concentration of 2.5 and 
5 mM of AAP. The activities of CYP3A4 were not changed by AAP and Ars 
treatments. The activities of CYP1A2 were increased by AAP, whereas 
it was decreased by Ars treatment. This study demonstrates that AAP 
is more serious hepatotoxicant compared to Ars. Ionizing radiation is 
Fig. 10: Neuronal differentiation of mesenchymal stem cells and measurement of neurotoxicity by different assays
Table 1: Some cardiotoxic agents
Class of drugs Drugs Induced toxicity Degree of incidence
Anthracyclines Doxorubicin Acute - arrhythmias Very frequent
Alkylating agents Cyclophosphamide Myocarditis, CHF Common
Ifosfamide Myocarditis, CHF
Cisplatin Ischemia, CHF
Antimetabolites 5-Fluorouracil Ischemia Common
Cepecitabine CHF Rare
Cytarabine Ischemia Rare
Other Coccain Ischemia, CHF Very frequent in Europian country and USA
CHF: Congestive heart failure
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often used to treat malignancies such as breast cancer, lymphoma, Ewing 
sarcoma, soft tissue sarcomas and rectal and anorectal carcinomas. At 
the same time, radiation can induce chromosomal and gene mutation. 
This can cause epigenetic changes of genome leading to many diseases 
like skin cancer and induce oxidative stress which in turn alters gene 
expression. The experimental data put forth by Cao et al. [69] indicate 
that irradiation produces free radicals that adversely affect the survival 
of MSCs in both distal and proximal femora of mouse. Irradiation injury 
to the vasculatures and the microenvironment affects the niches for 
stem cells during the recovery period. This study is further supported 
by the investigation undertaken by Cruet-Hennequart et al. [70] on 
human bone marrow-derived MSCs.
MSCS AND REPRODUCTIVE TOXICITY
EDs are naturally occurring compounds or man-made substances that 
interfere with the function of endocrine system of the body. EDs may be 
any estrogen-like and anti-androgenic chemicals, environmental agents 
(e.g., PCBs, DDT, dioxin, and some pesticides) or biological stressors like 
oxidative stress or pharmacological agents like radiation and drugs. 
Exposure to such toxic agents at any stage of embryonic development 
right from maturation of gonads to post-natal development may alter 
the transporter expression and activity that maintain fetal growth [9]. 
These agents may bring epigenetic modification of placental gene 
expression and cause disability, neuronal disorders and abnormal 
behavior in offspring. MSCs represent a good model to assess 
reproductive toxicants as these can be used to recapitulate the different 
stages of development by differentiating into the cells associated with 
reproduction (Fig. 11).
Recent studies have shown that MSCs under appropriate conditions can 
differentiate into various cell types including GCs. These studies also 
show that MSCs without any induction express some GC-specific genes 
innately. Moreover, one report suggests that female MSCs have a greater 
tendency to differentiate into female instead of male GCs and male 
BM-MSCs appeared more prone to differentiate into male rather than 
female GC. Recently, it is investigated that a rat model with damaged 
ovaries caused by using an anticancer agent, cyclophosphamide was able 
to restore ovarian function after transplantation of A-MSCs. So, MSCs 
were shown to be capable of inducing angiogenesis and restoring the 
number of ovarian follicles and corpora lutea in ovaries [71]. hUCMSCs 
can differentiate into PGC under specific in vitro condition [53]. Thus, 
MSCs represent a good model to assess reproductive toxicants as 
these can differentiate into different reproductive cells recapitulating 
different stages of development of GCs. But do MSCs establish all in vivo 
developmental patterns and phases in in vitro environment?
CONCLUSION
Today, modern society is more dependent on the use of a wide range 
of different chemicals that provide substantial and highly appreciated 
benefits, but at the same time, they have the potential to cause damages 
to the environment and human health. Toxicogenomic technologies can 
facilitate the screening of chemical compounds for their ability to cause 
toxicity. Recently pharmaceutical industries develop the most advanced 
toxicogenomic screening applications. This reflects incentives to 
screen out undesirable properties and more efficiently identify drug 
candidates with the safest and the most efficacious profiles. Further 
research is suggested to develop new assay for screening chemical 
toxicity using MSCs that would help the public about the risk factors 
associated with that chemicals.
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